Straits Times Index
3,338.67 -10.20 (-0.30%) Nikkei
38,690.67 -232.36 (-0.60%) Hang Seng
18,491.61 +88.57 (+0.48%) FTSE 100
8,262.75 -12.63 (-0.15%) Bitcoin USD
69,233.31 +500.01 (+0.73%) CMC Crypto 200
1,448.77 -19.17 (-1.31%)
MeiraGTx Holdings plc (MGTX)
After hours:
| Previous close | 4.9000 |
| Open | 4.9500 |
| Bid | 4.9100 x 100 |
| Ask | 4.9900 x 200 |
| Day's range | 4.8465 - 5.0250 |
| 52-week range | 3.4900 - 8.3500 |
| Volume | |
| Avg. volume | 162,688 |
| Market cap | 317.675M |
| Beta (5Y monthly) | 1.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) - Clinical development milestones met and remain on track for the re
- GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, Virtual Corporate presentation: Monday, April 29, 2024, at 11:00 a.m. ET BofA Securities Healthcare Conference 2024, Las Vegas
- GlobeNewswire
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held from April 16-20, 2024, at the Hyatt Regency Grand Cypress in Orlando, FL. The details of the oral presentation are below: Session: Oral Abstract Session IPresentation ID #196Title: Results of a Phase 1, Open-label, Dos
